{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Neurizon Therapeutics LTD.","description":"Neurizon Therapeutics LTD. (OTCQB: NUZTF) is an Australian clinical-stage biotech company focused on developing treatments for neurodegenerative diseases, with their lead program aimed at ALS. Michael Thurn, CEO and Managing Director of Neurizon, joins us to discuss their&amp;nbsp;mission to address neurodegenerative diseases through its lead ALS therapy &amp;nbsp;View Podcast Transcript ","author_name":"OTCQB Podcast","author_url":"http:\/\/otcmarketspodcast.libsyn.com\/otcqbpodcast","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39998135\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/198234395"}